New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2013
10:32 EDTREGN, BAYRYRegeneron says Eylea continues to exceed expectations
Comment made at the 31st Annual JP Morgan Healthcare Conference.
News For REGN;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
15:53 EDTBAYRYBayer working with Credit Suisse to explore diabetes unit sale, Bloomberg says
Subscribe for More Information
15:38 EDTBAYRYBayer considering sale of diabetes unit for up to $2.5B, Bloomberg reports
10:14 EDTBAYRYFDA grants QIDP designation to Bayer's Amikacin Inhale, Ciprofloxacin DPI
Subscribe for More Information
07:57 EDTBAYRYPerrigo confirms first to file patent challenge for generic version of Aveed
Subscribe for More Information
November 21, 2014
07:51 EDTREGNBofA/Merrill biotech analysts hold analyst/industry conference call
Subscribe for More Information
07:31 EDTREGNRegeneron price target raised to $462 from $418 at BofA/Merrill
Subscribe for More Information
November 20, 2014
08:36 EDTBAYRYZoetis guidance positive, says BMO Capital
Subscribe for More Information
07:47 EDTREGNRegeneron price target raised to $450 from $390 at Brean Capital
Subscribe for More Information
05:22 EDTREGNRegeneron, Sanofi receive FDA Breakthrough Therapy designation in AD
Subscribe for More Information
November 19, 2014
08:17 EDTREGNRegeneron, Sanofi report new data from six alirocumab trials
Subscribe for More Information
November 18, 2014
05:43 EDTREGN, BAYRYRegeneron announces EYLEA injection approved for DME treatment in Japan
Subscribe for More Information
November 14, 2014
07:14 EDTBAYRYAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
09:33 EDTBAYRYZoetis could get bought by Bayer for $53/share, says Jefferies
Subscribe for More Information
November 12, 2014
08:18 EDTBAYRYUBS to hold a conference
Subscribe for More Information
08:13 EDTREGNBoston Biotech to hold a conference
Subscribe for More Information
06:22 EDTBAYRYZoetis price target raised to $49 from $44 at Citigroup
Citigroup raised its price target for Zoetis (ZTS) shares to $49 after activist Pershing Square confirmed the accumulation of a 10% stake in the company. Citi thinks Pershing is interested in advocating for a sale of Zoetis, potentially to Valeant (VRX) if its bid for Allergan (AGN) fails. Citi believes others, including Bayer (BAYRY), could be interested in acquiring Zoetis. It keeps a Buy rating on the stock.
November 11, 2014
10:14 EDTREGNRegeneron data reinforce blockbuster potential of dupilumab, says Piper Jaffray
Piper Jaffray believes the Phase IIb results for dupilumab in patients with moderate to severe asthma reported by Regeneron (REGN) and partner Sanofi (SNY) reinforce the broad potential of the drug in a range of allergic diseases. The firm reiterates its $416 price target and Overweight rating on shares of Regeneron.
05:26 EDTREGNRegeneron, Sanofi announce dupilumab Phase 2b study met primary endpoint
Subscribe for More Information
November 10, 2014
16:07 EDTBAYRYUBS to hold a conference
UBS European Conference is being held in London, England on November 11-12.
07:19 EDTREGNCredit Suisse to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use